Show simple item record

dc.contributor.authorAndratschke, Nicolaus H.J.
dc.contributor.authorNieder, Carsten
dc.contributor.authorHeppt, Franz
dc.contributor.authorMolls, Michael
dc.contributor.authorZimmermann, Frank
dc.date.accessioned2016-03-04T14:01:22Z
dc.date.available2016-03-04T14:01:22Z
dc.date.issued2015-03-20
dc.description.abstractPurpose: To report on outcome and toxicity of stereotactic body radiotherapy (SBRT) for liver metastases in patients not eligible for surgery. <p>Methods: From 2000 to 2009, 74 patients with 91 liver metastases from different primaries have been treated with SBRT at our institution. Median planning target volume was 123 ccm (range: 10.6-1074 ccm). Treatment consisted of 3–5 fractions with 5–12.5 Gy/ fraction prescribed to the surrounding 60-95% isodose with daily image guidance. Regular follow-up included CT or MRI imaging until tumor progression. <p>Results: Median local recurrence-free interval was 23 months with a local control rate of 74.7%, 48.3% and 48.3% after 1, 2 and 3 years. Only minimum biologically effective dose (BED) to gross tumor volume (GTV) remained as independent significant factor for local control in multivariate analysis. No local recurrences were observed in lesions (n = 12) which received a minimal BED to the GTV of 120 Gy. Including 26 local recurrences, 67 patients (91%) showed disease progression after SBRT with a median time of 5 months. Median overall survival was 27 months with survival rates of 77%, 30% and 27% at 1, 3 and 5 years. On multivariate analysis only GTV volume remained as independent significant prognostic factor for overall survival (p = 0.002). No grade 3 to 5 acute toxicity and no grade 4 or 5 late toxicity occurred. <p>Conclusion: SBRT for liver metastases was well tolerated in this non-selected patient cohort and yielded good local control despite the considerable size of most lesions treated. Long-term survival is possible after SBRT.en_US
dc.descriptionLicense: Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)en_US
dc.identifier.citationRadiation Oncology 2015, 10:69en_US
dc.identifier.cristinIDFRIDAID 1259687
dc.identifier.doi10.1186/s13014-015-0369-9
dc.identifier.issn1748-717X
dc.identifier.urihttps://hdl.handle.net/10037/8710
dc.identifier.urnURN:NBN:no-uit_munin_8276
dc.language.isoengen_US
dc.publisherBioMed Centralen_US
dc.rights.accessRightsopenAccess
dc.subjectStereotactic radiotherapyen_US
dc.subjectSBRTen_US
dc.subjectLiveren_US
dc.subjectMetastasesen_US
dc.subjectVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Onkologi: 762en_US
dc.subjectVDP::Medical disciplines: 700::Clinical medical disciplines: 750::Oncology: 762en_US
dc.titleStereotactic radiation therapy for liver metastases: Factors affecting local control and survivalen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record